ViaDerma, Inc. has shown exemplary performance by releasing an innovative pharmaceutical product, Vitastem, in 2020. The pandemic year was full of hurdles to carry out quality research & development work. But still, ViaDerma managed to do so to provide effective pharmaceutical products.
Dr. Christopher Otiko has expressed that the FDA has approved the registration of a new 55 ml Vitastem spray bottle. It has come after many reputed hospitals tried & tested the product. Moreover, a major health insurance company has tested the Vitastem product successfully.
After the grant of approval by the FDA, ViaDerma’s Vitastem has started receiving a strong demand across the world. Viaderma, Inc. is currently in the final stages of talks with a major midwestern university, that has also carried out successful product testing, regarding the initial product purchase.
Vitastem is effective in treating various skin conditions and wounds due to which it enjoys a huge demand. The company president and CEO, Dr. Christopher Otiko, has anticipated the sales to reach 500,000 units in 2021.
ViaDerma has also secured an extended line of credit for financing future manufacturing. The company has also initiated discussions with a major worldwide medical nonprofit that has shown its interest in purchasing Vitastem. Doctors at this medical non-profit have asked for Vitastem spray to treat their patients from various severe infections.
Liberdol is another medicinal product that the company officially launched in 2020 and it is effective in relieving severe pain. Viastem is effective in curing bacterial infections associated with eczema, psoriasis, acne, diabetic wounds, cuts, etc. Due to this, it enjoys a big demand in the US and at a global level among patients.
